To JUPITER and beyond: Statins, inflammation, and primary prevention
Open Access
- 1 January 2010
- journal article
- editorial
- Published by Springer Nature in Critical Care
- Vol. 14 (3) , 310-3
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial)Critical Care, 2012
- Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial: study protocol for a randomized controlled trialTrials, 2012
- STATIN THERAPY IS COST-EFFECTIVE FOR VASCULAR EVENT PREVENTION IN ADULTS WITH ELEVATED C-REACTIVE PROTEIN: IMPLICATIONS OF JUPITERJACC, 2010
- Statins for sepsis: a critical and updated reviewClinical Microbiology and Infection, 2009
- A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsisIntensive Care Medicine, 2008
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Inflammatory Markers at Hospital Discharge Predict Subsequent Mortality after Pneumonia and SepsisAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Statin Treatment After Onset of Sepsis in a Murine Model Improves SurvivalCirculation, 2005
- HMG-CoA Reductase Inhibitor Simvastatin Profoundly Improves Survival in a Murine Model of SepsisCirculation, 2004
- Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular EventsNew England Journal of Medicine, 2002